239 related articles for article (PubMed ID: 27657335)
1. Dengue Protease Substrate Recognition: Binding of the Prime Side.
Lin KH; Nalivaika EA; Prachanronarong KL; Yilmaz NK; Schiffer CA
ACS Infect Dis; 2016 Oct; 2(10):734-743. PubMed ID: 27657335
[TBL] [Abstract][Full Text] [Related]
2. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
J Virol; 2017 May; 91(10):. PubMed ID: 28298600
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design.
Murthy HM; Judge K; DeLucas L; Padmanabhan R
J Mol Biol; 2000 Aug; 301(4):759-67. PubMed ID: 10966782
[TBL] [Abstract][Full Text] [Related]
4. Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides.
Niyomrattanakit P; Yahorava S; Mutule I; Mutulis F; Petrovska R; Prusis P; Katzenmeier G; Wikberg JE
Biochem J; 2006 Jul; 397(1):203-11. PubMed ID: 16489931
[TBL] [Abstract][Full Text] [Related]
5. Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses.
Rut W; Groborz K; Zhang L; Modrzycka S; Poreba M; Hilgenfeld R; Drag M
Antiviral Res; 2020 Mar; 175():104731. PubMed ID: 32014497
[TBL] [Abstract][Full Text] [Related]
6. Ligand-bound structures of the dengue virus protease reveal the active conformation.
Noble CG; Seh CC; Chao AT; Shi PY
J Virol; 2012 Jan; 86(1):438-46. PubMed ID: 22031935
[TBL] [Abstract][Full Text] [Related]
7. Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses.
Shiryaev SA; Kozlov IA; Ratnikov BI; Smith JW; Lebl M; Strongin AY
Biochem J; 2007 Feb; 401(3):743-52. PubMed ID: 17067286
[TBL] [Abstract][Full Text] [Related]
8. Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor.
Brinkworth RI; Fairlie DP; Leung D; Young PR
J Gen Virol; 1999 May; 80 ( Pt 5)():1167-1177. PubMed ID: 10355763
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
Erbel P; Schiering N; D'Arcy A; Renatus M; Kroemer M; Lim SP; Yin Z; Keller TH; Vasudevan SG; Hommel U
Nat Struct Mol Biol; 2006 Apr; 13(4):372-3. PubMed ID: 16532006
[TBL] [Abstract][Full Text] [Related]
10. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites.
Chanprapaph S; Saparpakorn P; Sangma C; Niyomrattanakit P; Hannongbua S; Angsuthanasombat C; Katzenmeier G
Biochem Biophys Res Commun; 2005 May; 330(4):1237-46. PubMed ID: 15823576
[TBL] [Abstract][Full Text] [Related]
11. Steady-state cleavage kinetics for dengue virus type 2 ns2b-ns3(pro) serine protease with synthetic peptides.
Khumthong R; Niyomrattanakit P; Chanprapaph S; Angsuthanasombat C; Panyim S; Katzenmeier G
Protein Pept Lett; 2003 Feb; 10(1):19-26. PubMed ID: 12625822
[TBL] [Abstract][Full Text] [Related]
12. Binding specificity of polypeptide substrates in NS2B/NS3pro serine protease of dengue virus type 2: A molecular dynamics Study.
Yotmanee P; Rungrotmongkol T; Wichapong K; Choi SB; Wahab HA; Kungwan N; Hannongbua S
J Mol Graph Model; 2015 Jul; 60():24-33. PubMed ID: 26086900
[TBL] [Abstract][Full Text] [Related]
13. Mutagenesis of the NS3 protease of dengue virus type 2.
Valle RP; Falgout B
J Virol; 1998 Jan; 72(1):624-32. PubMed ID: 9420267
[TBL] [Abstract][Full Text] [Related]
14. Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
Lai H; Teramoto T; Padmanabhan R
Methods Mol Biol; 2014; 1138():345-60. PubMed ID: 24696347
[TBL] [Abstract][Full Text] [Related]
15. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation.
Niyomrattanakit P; Winoyanuwattikun P; Chanprapaph S; Angsuthanasombat C; Panyim S; Katzenmeier G
J Virol; 2004 Dec; 78(24):13708-16. PubMed ID: 15564480
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal.
Viswanathan U; Tomlinson SM; Fonner JM; Mock SA; Watowich SJ
J Chem Inf Model; 2014 Oct; 54(10):2816-25. PubMed ID: 25263519
[TBL] [Abstract][Full Text] [Related]
17. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.
Wichapong K; Pianwanit S; Sippl W; Kokpol S
J Mol Recognit; 2010; 23(3):283-300. PubMed ID: 19693793
[TBL] [Abstract][Full Text] [Related]
18. Product release is rate-limiting for catalytic processing by the Dengue virus protease.
Shannon AE; Pedroso MM; Chappell KJ; Watterson D; Liebscher S; Kok WM; Fairlie DP; Schenk G; Young PR
Sci Rep; 2016 Nov; 6():37539. PubMed ID: 27897196
[TBL] [Abstract][Full Text] [Related]
19. Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects.
Murthy HM; Clum S; Padmanabhan R
J Biol Chem; 1999 Feb; 274(9):5573-80. PubMed ID: 10026173
[TBL] [Abstract][Full Text] [Related]
20. Discovering key residues of dengue virus NS2b-NS3-protease: New binding sites for antiviral inhibitors design.
Aguilera-Pesantes D; Robayo LE; Méndez PE; Mollocana D; Marrero-Ponce Y; Torres FJ; Méndez MA
Biochem Biophys Res Commun; 2017 Oct; 492(4):631-642. PubMed ID: 28343993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
